Sativex Summary of Product Characteristics
https://www.medicines.org.uk/emc/product/602/smpc
Sativex Summary of Product Characteristics
Re: Sativex Summary of Product Characteristics
April 11, 2015
A sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
http://www.thctotalhealthcare.com/a-sat ... sclerosis/
“Sativex® is an oromucosal spray, containing equivalent amounts of Δ9 -tetrahydrocannabinol (Δ9 -THC) and cannabidiol (CBD)-botanical drug substance (BDS), and which has been approved for the treatment of spasticity and pain associated to multiple sclerosis (MS).
In this study, we investigated whether Sativex® may also serve as a disease-modifying agent in the Theiler’s murine encephalomyelitis virus induced demyelinating disease model of MS…
The data support the therapeutic potential of Sativex® to slow MS progression and its relevance in CNS repair.”
A sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
http://www.thctotalhealthcare.com/a-sat ... sclerosis/
“Sativex® is an oromucosal spray, containing equivalent amounts of Δ9 -tetrahydrocannabinol (Δ9 -THC) and cannabidiol (CBD)-botanical drug substance (BDS), and which has been approved for the treatment of spasticity and pain associated to multiple sclerosis (MS).
In this study, we investigated whether Sativex® may also serve as a disease-modifying agent in the Theiler’s murine encephalomyelitis virus induced demyelinating disease model of MS…
The data support the therapeutic potential of Sativex® to slow MS progression and its relevance in CNS repair.”
https://www.eboro.cz
Re: Sativex Summary of Product Characteristics
2018 Dec
Nabiximols for multiple sclerosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299167/
..is the first cannabis-based medicine to be approved in Australia. It has been found to improve spasticity symptoms in less than half of patients. If improvements are not seen in the first four weeks, the patient is unlikely to benefit and treatment should be stopped.
wiki https://en.wikipedia.org/wiki/Nabiximols
Nabiximols for multiple sclerosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299167/
..is the first cannabis-based medicine to be approved in Australia. It has been found to improve spasticity symptoms in less than half of patients. If improvements are not seen in the first four weeks, the patient is unlikely to benefit and treatment should be stopped.
wiki https://en.wikipedia.org/wiki/Nabiximols
https://www.eboro.cz